Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer

Lung Cancer Clinical Trial

— LUCA-S  

Official title:

Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05621902
• Other study ID #: 102877
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 18, 2022
• Est. completion date: June 30, 2027

Study information

• Verified date: November 2022
• Source: Karolinska University Hospital
• Contact: Mats P Lambe, MD, PhD
• Phone: +46707715655
• Email: mats.lambe[@]ki.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.

Description:

This is a prospective, multicentre, randomized, two-armed, open-label trial in which participants will be randomised to standard follow-up according to current management guidelines for lung cancer (control arm) or with the addition of weekly web-based symptom monitoring (intervention arm). Both study groups will be asked to fill out quality of life questionnaires before randomisation and every three months. In addition to comparing survival and quality of life, the study will also assess progression free survival, performance status, eligibility for second line anti-neoplastic treatment and health care consumption. All subjects will be followed for 24 months. Updated data on survival will also be collected up to 5-years. By innovative use of an IT platform already in use in Swedish cancer care, this trial will evaluate potential benefits of systematic symptom monitoring in patients with advanced lung cancer. If corroborating earlier reports of marked survival benefits, the results of this trial could change clinical practice and current guidelines for follow-up of lung cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 398
• Est. completion date: June 30, 2027
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytology proven non-small cell lung cancer (NSCLC)
• NSCLC stage III or IV
• = 18 years
• ECOG performance status 0- 2
• Eligible patients should have initiated first-line treatment for advanced or metastatic disease with chemotherapy and/or immunotherapy, radiochemotherapy or targeted treatment
• Patients are eligible for inclusion if they have responded to first-line treatment with stable disease, or better, at the first radiological evaluation performed up to six months after start of treatment
• Stable disease, or better, on radiological assessment within 28 days of enrolment (CT scan or FDG-PET/CT. Cerebral MRI if known brain metastasis)
• Initial web-based application score of = 6
• Basic computer literacy
• Bank-ID (electronic identification system) and access to "1177 Vårdguiden"
• The subject has given written consent to participate in the study

Exclusion Criteria:

• Symptomatic brain metastases
• Pregnancy, breastfeeding, or planned pregnancy
• Persons under guardianship or deprived of liberty
• Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
• Treatment or disease which, according to the investigator, can affect treatment or study results
• Ongoing participation in another interventional clinical study

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• Weekly symptom monitoring
Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Mats Lambe	Gävle Hospital, Uppsala University Hospital

References & Publications (5)

Basch E, Snyder C. Overcoming barriers to integrating patient-reported outcomes in clinical practice and electronic health records. Ann Oncol. 2017 Oct 1;28(10):2332-2333. doi: 10.1093/annonc/mdx506. — View Citation

Denis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, Letellier C. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019 Jan 22;321(3):306-307. doi: 10.1001/jama.2018.18085. — View Citation

Nilsson J, Berglund A, Bergström S, Bergqvist M, Lambe M. The role of comorbidity in the management and prognosis in nonsmall cell lung cancer: a population-based study. Acta Oncol. 2017 Jul;56(7):949-956. doi: 10.1080/0284186X.2017.1324213. Epub 2017 May 9. — View Citation

Nipp R, Temel J. The Patient Knows Best: Incorporating Patient-Reported Outcomes Into Routine Clinical Care. J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx044. — View Citation

Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2017 Mar 10;35(8):834-841. doi: 10.1200/JCO.2016.70.5046. Epub 2016 Dec 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Overall survival	From date of randomization until the date of death from any cause, assessed up to 60 months.
Secondary	Progression free survival	First confirmed disease progression	From date of randomization until the date of first confirmed disease progression as judged by the investigator, assessed up to 24 months.
Secondary	Performance status	Performance status will be evaluated according to the ECOG Perfomance Status Scale (Scale 0-5: 0 = fully active, able to carry on all pre-disease performance without restriction, 5=dead).	At baseline and at each clinical visit (approximately every 3-4 months), assessed up to 24 months.
Secondary	Proportion of patients starting second-line anti-neoplastic treatment	Proportion of patients starting second-line anti-neoplastic treatment within 12 weeks from date of confirmed disease progression after randomization.	Assessed up to 24 months.
Secondary	Quality of life	Assessed by EORTC QLQ-C30-LC13 questionnaire. The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.	At baseline and every three months, assessed up to 24 months.
Secondary	Symptoms of depression	Assessed by the Patient Health Questionnaire (PHQ9). Score 0 (no symptoms) to 27 (severe symptoms).	At baseline and every three months, assessed up to 24 months.
Secondary	Number of days of in-hospital care	Health care consumption will be assessed as number of days of in-hospital care during study participation.	Assessed up to 24 months.